COMMENTARY

• How to Eliminate Concerns about Safety of Liovel
  October 4, 2010

• Will It Be Possible to Eliminate Unnecessary Equivalence Studies for Generics?
  September 20, 2010

• Big Pharma Losing Flagships within a Few Years and Shifting Paradigm
  September 13, 2010

• Prior Assessment System Is One Step Forward to Quicker NDA Review
  August 2, 2010

• Industry Needs to Form Consensus on Premium with Med. Institutions
  July 26, 2010

• Japan Should Promote Personalized Cancer Treatment
  July 26, 2010

• METI Reports on “Patent Box”Taxation System in Its Vision 2010
  July 5, 2010

• How Will Generics-Only Companies Will Compete with Major New Entrants?
  June 28, 2010

• Mr Hasegawa Calls For Cooperation with Asian Countries
  June 21, 2010

• PMDA Consultation for Clinical Drug Development in Japan
  April 26, 2010

• Taiyo Needs to Restart from Scratch
  April 19, 2010

• Drug Companies Have No Time to Lose under New Pricing System
  March 29, 2010

• Wholesalers, Pharmacy Chains to Ally to Improve Their Business
  March 22, 2010

• New Pricing System Gives Makers Good Chance to Break from Old Business Practices
  March 8, 2010

• Transfer Limited Financial Resources to Parties Who Make Effort to Provide Better Services
  March 1, 2010

• Korosho Moves to Change Its Vaccine Policy
  February 22, 2010

• Prospects of the Japanese Pharmaceutical Industry in 2010
  February 15, 2010

• Number of Entrants into Market for Biosimilars Increases, But Barriers Are Still High
  February 8, 2010

• New Pricing System to Make e-Detailing More Important
  February 1, 2010

• Number of Holders of Designated Disease Treatment Beneficiary Certificate Up to 647,604
  November 30, 2009

ページ